Genotyping and drug susceptibility profiling of Prototheca sp. strains isolated from cases of protothecosis in dogs.

Autor: Proskurnicka A; Department of Medical Microbiology, Institute of Microbiology, Faculty of Biology, University of Warsaw, Warsaw, Poland., Iskra M; Department of Medical Microbiology, Institute of Microbiology, Faculty of Biology, University of Warsaw, Warsaw, Poland., Wronka S; Department of Medical Microbiology, Institute of Microbiology, Faculty of Biology, University of Warsaw, Warsaw, Poland., Bakuła Z; Department of Medical Microbiology, Institute of Microbiology, Faculty of Biology, University of Warsaw, Warsaw, Poland., Danesi P; Istituto Zooprofilattico Sperimentale delle Venezie, Padua, Italy., de Farias MR; Postgraduate Program in Animal Science, Pontifical Catholic University of Paraná, Curitiba, Brazil., Ramos Portilho FV; Department of Animal Production and Preventive Veterinary Medicine, São Paulo State University, Botucatu, Brazil., Garcia Ribeiro M; Department of Animal Production and Preventive Veterinary Medicine, São Paulo State University, Botucatu, Brazil., Rösler U; Institute for Animal Hygiene and Environmental Health, Freie Universitaet Berlin, Berlin, Germany., Kano R; Department of Veterinary Dermatology, Nihon University School of Veterinary Medicine, Fujisawa, Kanagawa, Japan., Malik R; Centre for Veterinary Education, Sydney School of Veterinary Science, The University of Sydney, Sydney, Australia., Jagielski T; Department of Medical Microbiology, Institute of Microbiology, Faculty of Biology, University of Warsaw, Warsaw, Poland.
Jazyk: angličtina
Zdroj: Journal of veterinary internal medicine [J Vet Intern Med] 2025 Jan-Feb; Vol. 39 (1), pp. e17173. Date of Electronic Publication: 2024 Nov 20.
DOI: 10.1111/jvim.17173
Abstrakt: Background: Protothecosis in dogs is a rare, yet emerging disease, distinguished by its often-aggressive clinical course and high fatality rate. Our study was conducted to enhance treatment protocols for affected dogs by better understanding the genetic diversity and drug resistance patterns of Prototheca species.
Objectives: To identify species and drug susceptibility profiles of an international collection of 28 Prototheca strains isolated from cases of protothecosis in dogs.
Animals: None.
Methods: Retrospective study. Species-level identification was made for isolates from 28 dogs in 6 countries by molecular typing with the partial cytb gene as a marker. For the determination of minimum inhibitory concentrations (MICs) and minimum algicidal concentrations (MACs), the Clinical Laboratory Standards Institute (CLSI) protocol (M27-A3) was used.
Results: Prototheca bovis was the most prevalent species, accounting for 75% (21/28) of the cases, followed by P. wickerhamii (18%; 5/28) and P. ciferrii (7%; 2/28). Of the 6 drugs tested, efinaconazole (EFZ) was the most potent in vitro, with its median MIC and MAC values equal to 0.125 mg/L. The lowest activity was found for fluconazole (FLU), with MIC and MAC medians of 48 mg/L and 64 mg/L, respectively.
Conclusions and Clinical Importance: Our study identifies P. bovis as the species that most frequently causes protothecosis in dogs, which suggests the possibility of cross-species infection from other animals, especially cows. Additionally, it indicates that EFZ could be used in the treatment of infection in the colon.
(© 2024 The Author(s). Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine.)
Databáze: MEDLINE
Externí odkaz: